TFSA Investors: Avoid These 2 Sectors to Protect Your Wealth 

Sectors like biotech and construction don’t offer rewards that match their risks. I stay away.

Modern buildings in business district

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

My tax-free savings account (TFSA) is my sacred nest egg. I pour savings into the account and maximize the TFSA contribution limit every year with the intention of leaving money there until I retire. With that multiple-decade time horizon in mind, my greatest fear is that this money will lose its value over time. 

Any experienced investor will tell you that losing money is dramatically worse than gaining an equal amount. If a stock loses 50% of its value, for example, it could take nearly 10 years for it to recover to its original price even if it grows at a 7% annualized rate. Most stocks don’t even come close to that rate of appreciation. 

So, while much of the content published on this site focuses on the best stocks to invest in and the most attractive opportunities, I want to spend time discussing the least attractive and most speculative industries long-term investors should stay away from. 

Biotech

Probably my least favourite industry to invest in is the biotechnology sector. Unlike regular technology companies, innovators in this sector can’t simply move fast and break things. The pharmaceutical industry is heavily regulated, which means getting a drug to market is an unbelievably difficult task. 

On average, 80% of all new drugs that are sent to trial fail to every make it to the market. Meanwhile, biotech companies must spend millions or even billions of dollars getting their drugs through the various regulatory hurdles and clinical trials. 

Larger biotech stocks with more financial resources and broader pipelines of potential drugs, like Bellus Health, can probably weather the occasional failure, but smaller companies in this sector risk bankruptcy if a drug fails. Recently closed companies such as Ambrilia Biopharma and BioAmber are just a few examples of this.

Construction

The construction of new infrastructure and real estate is vital to any economy; however, construction companies face massive costs and an unpredictable cycle that makes their business model inherently risky. 

Across the world, construction companies contributed the highest portion of failed businesses (20%). In the United States, more than a third (36.8%) of construction contractors go out of business before they complete their first year of operation. 

Contractors face a long list of challenges that include a high regulatory burden, unpredictable weather, volatile raw material prices, insurance premiums and interest rate sensitivity.

When the real estate market cycle dips or a recession hits, most these construction companies struggle to keep their projects going or funded. 

A good example is Bird Construction Inc., which has lost nearly 52.8% of its value since 2011, even though the value of real estate and the pace of construction across Canada has skyrocketed over that period.    

Foolish takeaway

Investors cannot reap handsome rewards without any risk. However, in the case of the aforementioned industries, the risk-reward ratio is simply skewed.

When 80% of new drugs fail to pass trials and a third of new construction companies go out of business in less than a year, there’s no way the potential rewards can offset the risk. 

There’s plenty of other opportunities in Canada’s dynamic economy for TFSA investors like me, so there’s no reason why I can’t avoid these two volatile industries forever. 

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Vishesh Raisinghani has no position in the companies mentioned. 

More on Investing

Investing

KM Throwaway Post

Read more »

Investing

Carlos Test Yoast Metadata

Read more »

Investing

KM Ad Test

This is my excerpt.

Read more »

Investing

Test post for affiliate partner mockups

Updated: 9/17/2024. This post was not sponsored. The views and opinions expressed in this review are purely those of the…

Read more »

Investing

Testing Ecap Error

Premium content from Motley Fool Stock Advisor We here at Motley Fool Stock Advisor believe investors should own at least…

Read more »

Investing

TSX Today: Testing the Ad for James

la la la dee dah.

Read more »

Lady holding remote control pointed towards a TV
Investing

2 Streaming Stocks to Buy Now and 1 to Run From

There are streaming stocks on the TSX that are worth paying attention to in 2023 and beyond.

Read more »

A red umbrella stands higher than a crowd of black umbrellas.
Stocks for Beginners

Top Recession-Resilient TSX Stocks to Buy With $3,000

It's time to increase your exposure to defensives!

Read more »